🚀 Science
Prices of 543 cancer medicine brands cut, some by nearly 90%, from 9 November
In 60 seconds: The National Pharmaceutical Pricing Authority (NPPA) has cut the maximum retail prices of 543 brands of cancer medicines, with the new rates applying from 9 November. A 10-tablet pack of the breast cancer drug Anarzole falls from ₹695.76 to ₹73, and a vial of Abbott's Bevacizab from ₹21,767.70 to ₹5,930. The cuts follow the regulator's 17 October order capping trade margins on 137 cancer drugs at 30%.
Why it matters
Cancer medicines can cost thousands of rupees a dose and push families into debt. Lower prices can help more patients afford and complete their treatment.
Explain it simply
If a packet of tea leaves the factory at ₹50 but shops sell it at ₹500, the extra is markup. The government has now limited that markup on cancer drugs.
The 3-minute read
What happened
Other examples: RPG Life Sciences' Fulbreca vial falls from ₹26,072.16 to ₹5,491, its Debrumab syringe from ₹22,031.25 to ₹5,941, and Natco's Dasanat 20 pack of 60 tablets from ₹2,812.50 to ₹1,085.93.
Background
The 30% cap on trade margins was applied under Paragraph 19 of the Drugs (Prices Control) Order, 2013, which lets the government act on prices in the public interest.
How it works
A trade margin is the gap between the price at which a company first sells a medicine and the MRP paid by the patient. Capping it forces companies to lower the printed MRP.
What's next
Chemists and hospitals must charge and display the new prices from 9 November. The list, based on company data up to 27 October, will be updated as more firms submit prices.
What it means for you
If you or a relative buy cancer medicines, check the MRP after 9 November; NPPA's Pharma Sahi Daam app shows official prices.
Key numbers
- 543: Cancer medicine brands with lower MRPs
- 137: Cancer drugs under the trade margin cap
- 30%: Maximum trade margin allowed
- 9 Nov: Date new prices apply
Both sides
- The government: Capping trade margins curbs excessive markups and brings immediate relief to cancer patients.
- Cautious observers: The cut covers only the listed brands, so patients should check the new MRP on packs from 9 November.
Key terms explained
- Trade margin
- The markup added by distributors and retailers between the maker's selling price and the MRP.
- Maximum retail price
- The highest price, printed on the pack, that a shop can charge a customer.
The story so far
- Feb 2019: NPPA caps trade margins on 42 non-scheduled anti-cancer drugs at 30%. In 2019 the regulator limited trade margins on 42 cancer drugs as a pilot, bringing down the prices of hundreds of brands.
- 17 Oct 2026: NPPA caps trade margins on 137 non-scheduled anti-cancer drugs at 30%. The new order covers immunotherapy medicines for more than 20 cancer types, denosumab for breast and prostate cancer, pegfilgrastim and bevacizumab.
- Today: NPPA cuts MRPs of 543 cancer medicine brands from 9 November
Exam notes (UPSC, SSC, Banking, PSC)
- The National Pharmaceutical Pricing Authority (NPPA) was set up in 1997 under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- The Drugs (Prices Control) Order, 2013 is issued under the Essential Commodities Act, 1955.
- Scheduled drugs are those in the National List of Essential Medicines (NLEM); their ceiling prices are fixed by NPPA.
- For non-scheduled drugs, companies may raise the MRP by at most 10% a year.
Likely exam question: How does India regulate medicine prices? Discuss the role of the NPPA and the trade margin rationalisation approach.